GlucoTrack Inc.

01/13/2025 | Press release | Distributed by Public on 01/13/2025 16:29

Private Placement Form 8 K

Item 3.02. Unregistered Sales of Equity Securities.

As previously disclosed, on November 12, 2024, Glucotrack, Inc., a Delaware corporation (the "Company") commenced a best efforts public offering (the "Offering"), and in connection with such Offering and in private transactions that took place concurrently with such Offering, issued an aggregate of 10,030,145 Series B Warrants (the "Series B Warrants") to purchase common stock, par value $0.001 per share of the Company.

Beginning on January 6, 2025 , through January 13, 2025, the Company received exchange notices from certain holders of the Series B Warrants, with respect to an aggregate of 6,950,240 of the Series B Warrants, requiring the delivery of 134,785,015 shares of Common Stock. The remaining 3,079,905 Series B Warrants are exchangeable for an aggregate of approximately 19,909,386 shares of Common Stock (subject to adjustment in the event of any stock dividend and split, reverse stock split, recapitalization, reorganization or similar transaction).

The Series B Warrants contained an alternative cashless exercise feature, pursuant to which the holder of a Series B Warrant could exchange such Series B Warrant to acquire, on a cashless basis, additional shares of Common Stock, pursuant to a formula set forth in the Series B Warrants that provided for the acquisition of up to 300% of the number of shares that could otherwise be purchased under such Series B Warrant pursuant to a cash exercise of such Series B Warrant.

The issuance of Common Stock was made pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), provided by Section 3(a)(9) of the Securities Act, on the basis that (a) the shares of Common Stock were issued in exchange for other outstanding securities of the Company; (b) there was no additional consideration delivered by the holder in connection with the exchange; and (c) there were no commissions or other remuneration paid by the Company in connection with the exchange.